

Dungee

Receipt

Atty. Dkt. No. 072121-0139

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul A. Renhowe  
Title: Heterocyclic Compounds  
Appl. No.: 09/943,382  
Filing Date: 08/30/2001  
Examiner: R. Desai  
Art Unit: 1625

<p><b>CERTIFICATE OF MAILING</b></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.</p> <p><b>Bernard P. Friedrichsen</b> (Printed Name)</p> <p><i>Bernard P. Friedrichsen</i> (Signature)</p> <p><b>March 26, 2004</b> (Date of Deposit)</p>
--

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Attn: Appl. Processing Division, Customer Correction Branch

Sir:

Attached is a copy of the Replacement Filing Receipt received from the PTO in the above-referenced application.

There is an error with respect to the title. The title should read: **HETEROCYCLIC DERIVATIVES OF QUINOLINONE BENZIMIDAZOLES.**

The correction is not due to any error by Applicant and, accordingly, no fee is due. Issuance of a corrected Filing Receipt is respectfully requested.


Respectfully submitted,

Date March 26, 2004

FOLEY & LARDNER LLP  
Customer Number: 23524  
Telephone: (608) 258-4281  
Facsimile: (608) 258-4258

By *Bernard P. Friedrichsen*

Bernard P. Friedrichsen  
Attorney for Applicant  
Registration No. 44,689

**COPY**

Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/943,382	08/30/2001	1625	888	072121:0139		21	2

CHIRON CORPORATION  
 INTELLECTUAL PROPERTY  
 P.O. BOX 8097  
 EMERYVILLE, CA 94662-8097

CONFIRMATION NO. 7754

REPLACEMENT FILING RECEIPT



\*OC000000012202868\*

Date Mailed: 03/26/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Paul A. Renhowe, Danville, CA;  
 Timothy Machajewski, Martinez, CA;  
 Cynthia M. Shafer, El Sobrante, CA;  
 Mary Ellen Wernette-Hammond, Castro Valley, CA;  
 Sabina Pecchi, Oakland, CA;

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/231,829 09/01/2000

**Foreign Applications**

If Required, Foreign Filing License Granted: 10/05/2001

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

**Title**

HETEROCYCLIC DERIVATIVES OF QUINOLINONE BENZIMIDAZOLES

to name BENZIMIDAZOLES

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).